Takeaway

• Among people with type 2 diabetes (T2D), use of sodium-glucose cotransporter-2 inhibitors (SGLT2is) was associated with 18% reduced risk for major adverse cardiac and cerebrovascular events (MACCE) and 51% lower risk for heart failure (HF), while glucagon-like peptide-1 receptor agonist (GLP-1RA) use was also associated with an 18% lower HF...